Source: Eur Respir J 2009; 34: 1093-1099
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Austin E. D., Cogan J. D., West J. D., Hedges L. K., Hamid R., Dawson E. P., Wheeler L. A., Parl F. F., Loyd J. E., Phillips J. A. III. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009; 34: 1093-1099

Member's Comments

No comment yet.

Related content which might interest you: BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Source: Eur Respir J 2002; 20: 518-523 Year: 2002 Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017 Year: 2017 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017 Year: 2017 BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Source: Eur Respir J 2004; 24: 371-374 Year: 2004 Estrogen receptor alpha gene polymorphisms and primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Expression of fetal genes in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003 Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018 Year: 2019 Pathobiology of pulmonary arterial hypertension and right ventricular failure Source: Eur Respir J 2012; 40: 1555-1565 Year: 2012 First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Association of VDR, COL1A1 and CALCR genes polymorphisms with susceptibility to steroid osteoporosis in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension Source: Eur Respir J 2009; 34: 1100-1110 Year: 2009 Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 BMPR2 mutations and iron metabolism in pulmonary arterial hypertension patients Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Clinical characteristics, hemodynamics and survival in idiopathic and familial pulmonary arterial hypertension with germline BMPR2 mutation Source: Eur Respir J 2007; 30: Suppl. 51, 250s Year: 2007